Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors?
Authors' conclusion
Glucocorticoids, at the dosages used to treat ICI-treated patients with RA and mNSCLC, had a negligible effect on survival in the 91 days after ICI initiation.
Study context
- Population
- Medicare patients with rheumatoid arthritis (RA) aged ≥66 years, RA diagnosed before metastatic non-small cell lung cancer (metastatic nonsmall cell lung cancer (mNSCLC)), initiating nivolumab, pembrolizumab or atezolizumab (2015–2019)mean age 75 years
- Participants
- 663 patients
- Exposure
- Early GC use vs no GC use
- GCn = 363
- Outcome
- Survival, GC use (time-varying Cox model)
Methodological detailsMedicare cohort, landmark Kaplan-Meier analysis, time-varying adjusted Cox models
- Medicare cohort
- Landmark Kaplan-Meier analysis
- Time-varying adjusted Cox models
Main finding
As reported in the abstract
- GC use was not associated with survival
Observational data: associations, not effects.
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Are Glucocorticoids Associated With Worse Survival Among Patients With Rheumatoid Arthritis and Lung Cancer Treated With Immune Checkpoint Inhibitors? Arthritis Rheumatol. Published 29 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →